W
Wilson I. Gonsalves
Researcher at Mayo Clinic
Publications - 391
Citations - 6500
Wilson I. Gonsalves is an academic researcher from Mayo Clinic. The author has contributed to research in topics: Multiple myeloma & Medicine. The author has an hindex of 36, co-authored 329 publications receiving 4393 citations. Previous affiliations of Wilson I. Gonsalves include University of Rochester & Creighton University Medical Center.
Papers
More filters
Journal ArticleDOI
Improved outcomes for newly diagnosed AL amyloidosis between 2000 and 2014: cracking the glass ceiling of early death.
Eli Muchtar,Morie A. Gertz,Shaji Kumar,Martha Q. Lacy,David Dingli,Francis K. Buadi,Martha Grogan,Suzanne R. Hayman,Prashant Kapoor,Nelson Leung,Amie Fonder,Miriam Hobbs,Yi Lisa Hwa,Wilson I. Gonsalves,Rahma Warsame,Taxiarchis Kourelis,Stephen J. Russell,John A. Lust,Yi Lin,Ronald S. Go,Steven R. Zeldenrust,Robert A. Kyle,S. Vincent Rajkumar,Angela Dispenzieri +23 more
TL;DR: Overall, outcomes among patients with AL amyloidosis have improved with earlier diagnosis, higher rates of VGPR, lower early mortality, and improved OS.
Journal ArticleDOI
Impact of primary molecular cytogenetic abnormalities and risk of progression in smoldering multiple myeloma
S V Rajkumar,Vivek Gupta,R Fonseca,Angela Dispenzieri,Wilson I. Gonsalves,Dirk R. Larson,Rhett P. Ketterling,John A. Lust,Robert A. Kyle,Shaji Kumar +9 more
TL;DR: Overall survival from diagnosis of SMM was significantly inferior with t(4;14) compared with t (11;14), median 105 versus 147 months, respectively, and there was a trend to shorter TTP with deletion 17p.
Journal ArticleDOI
Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria.
Arjun Lakshman,S. Vincent Rajkumar,Francis K. Buadi,Moritz Binder,Morie A. Gertz,Martha Q. Lacy,Angela Dispenzieri,David Dingli,Amie Fonder,Suzanne R. Hayman,Miriam Hobbs,Wilson I. Gonsalves,Yi Lisa Hwa,Prashant Kapoor,Nelson Leung,Ronald S. Go,Yi Lin,Taxiarchis Kourelis,Rahma Warsame,John A. Lust,Stephen J. Russell,Steven R. Zeldenrust,Robert A. Kyle,Shaji Kumar +23 more
TL;DR: Patients with high-risk SMM need close follow-up and are candidates for clinical trials aiming to prevent progression, and BMPC%, M-protein, and FLCr at diagnosis can be used to risk stratify patients with SMM.
Journal ArticleDOI
Patient and Tumor Characteristics and BRAF and KRAS Mutations in Colon Cancer, NCCTG/Alliance N0147
Wilson I. Gonsalves,Michelle R. Mahoney,Daniel J. Sargent,Garth D. Nelson,Steven R. Alberts,Frank A. Sinicrope,Richard M. Goldberg,Paul J. Limburg,Stephen N. Thibodeau,Axel Grothey,Joleen M. Hubbard,Emily Chan,Suresh G. Nair Md,Jeffrey L. Berenberg,Robert R. McWilliams +14 more
TL;DR: Specific patient and tumor characteristics are associated with KRAS and BRAF (V600E) mutations.
Journal ArticleDOI
Therapy for Relapsed Multiple Myeloma: Guidelines From the Mayo Stratification for Myeloma and Risk-Adapted Therapy.
David Dingli,Sikander Ailawadhi,P. Leif Bergsagel,Francis K. Buadi,Angela Dispenzieri,Rafael Fonseca,Morie A. Gertz,Wilson I. Gonsalves,Susan R. Hayman,Prashant Kapoor,Taxiarchis Kourelis,Shaji Kumar,Robert A. Kyle,Martha Q. Lacy,Nelson Leung,Yi Lin,John A. Lust,Joseph R. Mikhael,Craig B. Reeder,Vivek Roy,Stephen J. Russell,Taimur Sher,A. Keith Stewart,Rahma Warsame,Stephen R. Zeldenrust,S. Vincent Rajkumar,Asher A. Chanan Khan +26 more
TL;DR: The latest recommendations on the diagnostic evaluation of relapsed multiple myeloma and decision trees on how to treat patients at various stages of their relapse are provided together with the evidence to support them.